Regardless of the sequential decrease in Current Liabilities, during the first quarter 2025, Quick Ratio deteriorated to 0 a new company low.

Within Biotechnology & Pharmaceuticals industry 158 other companies have achieved higher Quick Ratio than Nkgen Biotech Inc in first quarter 2025. While Quick Ratio total ranking has improved so far during the Q1 2025 to 4357, from total ranking in the fourth quarter 2024 at 4570.

Explain Quick Ratio?
How much Cash & cash equivalents NKGN�s has?
What are NKGN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NKGN Quick Ratio	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1
Y / Y Current Liabilities Change	17.09 %	44.92 %	-4.45 %	715.77 %	962.44 %
Y / Y Cash & cash equivalent Change	-82.35 %	307.69 %	-99.91 %	90.55 %	-83.56 %
Quick Ratio MRQ	0	0	0	0	0
NKGN's Total Ranking	# 4357	# 4570	# 4632	# 4376	# 3189
Seq. Current Liabilities Change	-24.29 %	56.18 %	-27.8 %	37.15 %	-6.3 %
Seq. Cash & cash equivalent Change	-94.34 %	1225 %	-89.87 %	132.35 %	30.77 %

Quick Ratio first quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 159
Healthcare Sector	# 958
Overall Market	# 4357

Quick Ratio Statistics
High	Average	Low
7.51	0.79	0
(Jun 30 2021)		(Mar 31 2025)

Financial Statements
Nkgen Biotech Inc 's Current Liabilities	$ 44 Millions	Visit NKGN's Balance sheet
Nkgen Biotech Inc 's Cash & cash equivalent	$ 0 Millions	Visit NKGN's Balance sheet
Source of NKGN's Sales		Visit NKGN's Sales by Geography

Cumulative Nkgen Biotech Inc 's Quick Ratio

NKGN's Quick Ratio for the trailling 12 Months

NKGN Quick Ratio	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	55.24 %	107.46 %	213.75 %	896.19 %	815.66 %
Y / Y Cash & cash equivalent TTM Growth	-97.76 %	-97.49 %	-98.39 %	716.36 %	284.43 %
Quick Ratio TTM	0	0	0	0.05	0.07
Total Ranking TTM	# 3542	# 3816	# 3657	# 3662	# 2567
Seq. Current Liabilities TTM Growth	3.48 %	10.82 %	-1.03 %	36.78 %	38.29 %
Seq. Cash & cash equivalent TTM Growth	-12.33 %	54.42 %	-98.35 %	0.42 %	-1.91 %

Quick ratio ranking by company, industry and sector >> Back to NKGN Financial Strength Comparisons >> Go to Compare NKGN Quick Ratio to its Competitors

News about Nkgen Biotech Inc Quick Ratio

NKGen Biotech Secures $5 Million in Additional Financing to Drive Clinical Program Advancements

Introduction
NKGen Biotech Inc, a leading biotechnology company focused on neurodegenerative diseases, has announced significant progress in its clinical programs for Alzheimer s and Parkinson s diseases. Alongside this positive development, the company has also secured an additional $5 million in financing to further drive its research and development efforts.
Progress in Neurodegenerative Clinical Program
NKGen Biotech Inc s neurodegenerative clinical program continues to move forward smoothly, with significant advancements observed in the Phase 2 trial for Alzheimer s disease. The company remains on track and anticipates the initiation of the Phase 1/2a trial for Parkinson s disease in the near future. These milestones represent crucial steps towards finding potential treatments for these debilitating conditions, addressing the significant unmet medical needs in this space.

On the trailing twelve months basis In Spite of the decline in Current Liabilities in the Q1 2025 to $43.89 millions, cumulative Quick Ratio